Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026)

Intellia Therapeutics has reported Non Operating Investment Income over the past 8 years, most recently at -$904000.0 for Q1 2026.

  • Quarterly Non Operating Investment Income fell 300.0% to -$904000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Mar 2026, up 94.79% year-over-year, with the annual reading at -$32.6 million for FY2024, 995.87% down from the prior year.
  • Non Operating Investment Income was -$904000.0 for Q1 2026 at Intellia Therapeutics, down from -$385000.0 in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $3.6 million in Q4 2023 and troughed at -$20.4 million in Q2 2024.
  • The 5-year median for Non Operating Investment Income is -$904000.0 (2026), against an average of -$2.2 million.
  • The largest YoY upside for Non Operating Investment Income was 715.53% in 2022 against a maximum downside of 93100.0% in 2022.
  • A 5-year view of Non Operating Investment Income shows it stood at $3.4 million in 2022, then increased by 5.91% to $3.6 million in 2023, then plummeted by 184.79% to -$3.1 million in 2024, then soared by 87.51% to -$385000.0 in 2025, then tumbled by 134.81% to -$904000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Non Operating Investment Income are -$904000.0 (Q1 2026), -$385000.0 (Q4 2025), and $337000.0 (Q3 2025).